Skip to main content

Table 2 Antidepressant use and associated risk of head injury among persons with Alzheimer’s disease

From: Risk of head and traumatic brain injuries associated with antidepressant use among community-dwelling persons with Alzheimer’s disease: a nationwide matched cohort study

  Number of events Person years Age-adjusted event rate per 100 person-years (95% CI) Unadjusted HR (95% CI) Adjusted HR (95% CI)a Propensity score adjusted HR (95% CI)
Users compared with nonusers
 Nonusers 981 47,423 2.43 (2.06–2.35) Reference Reference Reference
 Users 392 13,178 2.98 (2.49–3.06) 1.38 (1.23–1.55) 1.36 (1.21–1.53) 1.35 (1.20–1.52)
Antidepressant use classified according to duration of use
 1–30 days 37 877 3.97 (2.70–5.25) 2.15 (1.35–3.41) 2.12 (1.33–3.36) 1.71 (1.10–2.66)
 31–180 days 102 3152 3.09 (2.49–3.70) 1.27 (1.00–1.61) 1.25 (1.00–1.59) 1.35 (1.06–1.71)
 181–365 days 84 2669 3.07 (2.41–3.73) 1.35 (1.05–1.75) 1.33 (1.03–1.72) 1.35 (1.05–1.75)
 366–731 days 90 3289 2.64 (2.10–3.18) 1.29 (1.01–1.64) 1.27 (1.00–1.62) 1.28 (1.01–1.63)
  > 731 days 79 3213 2.29 (1.56–3.01) 1.50 (1.17–1.93) 1.48 (1.15–1.91) 1.35 (1.05–1.74)
Drug class specific analyses (n = 38 concomitant users excluded)
 Other antidepressant 110 4465 2.24 (1.78–2.71) 1.01 (0.83–1.23) 0.95 (0.77–1.16) 0.94 (0.77–1.15)
 SSRI 246 7664 2.74 (2.40–3.99) 1.32 (1.15–1.52) 1.28 (1.11–1.48) 1.26 (1.10–1.45)
As-treated analyses restricted to the first 180 days
 Nonusers 248 9758 2.33 (2.03–2.63) Reference Reference Reference
 Users 139 4032 3.29 (2.74–3.84) 1.36 (1.11–1.68) 1.31 (1.06–1.62) 1.34 (1.08–1.66)
Intention-to-treat analyses restricted to the first 180 days
 Nonusers 268 10,226 2.35 (2.05–2.65) Reference Reference Reference
 Users 173 5060 3.25 (2.76–3.75) 1.31 (1.08–1.58) 1.26 (1.03–1.53) 1.34 (1.10–1.64)
  1. The reference category in all analyses is nonuse
  2. aAdjusted for cardiovascular disease, diabetes, asthma/COPD, epilepsy, substance abuse, cancer, schizophrenia, bipolar disorder or depression, baseline use of antipsychotics, opioids and benzodiazepines and related drugs, history of stroke and hip fracture, and socioeconomic position
  3. CI confidence interval, HR hazard ratio, SSRI selective serotonin reuptake inhibitor
Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193